New hep C treatment
Thursday, 2 August 2018
A new hepatitis C treatment, Maviret®, was added to the Pharmaceutical Benefits Scheme on 1 August 2018.
This is another important step in the Australian government commitment to eliminating hepatitis C by 2030.
The treatment course for Maviret® is 3 tablets once a day for 8 weeks and is suitable for all genotypes, including people with cirrhosis. It is a valuable additional treatment option for the small number of people who were not cured with their first round of DAA treatment.
The new treatments for hepatitis C are quick, easy and have a very high cure rate. They have few, if any, side-effects.
People with bleeding disorders and hepatitis C are now encouraged to talk to their Haemophilia Treatment Centre or GP to see what see what arrangements can be made to have their hep C tests and treatments locally. The GP fact sheet on bleeding disorders and hep C has been developed by the Australian Haemophilia Centre Directors’ Organisation and HFA to support this.
HFA marked World Hepatitis Day on 28 July with a renewed effort to reach the people with bleeding disorders and hepatitis C who have not yet taken up treatment – or perhaps don’t even know they have hep C.
Join us in spreading the message! Visit the HFA World Hepatitis Day page for more information
Get the latest free Acrobat Reader to read PDF documents
Date last reviewed: 2 August 2018